4H-pyrido[1,2-a]pyrimidine | 255-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 4H-pyrido[1,2-a]pyrimidine
• 英文别名: Pyrido[1,2-a]pyrimidine；4H-pyrido[1,2-a]pyrimidine
• CAS: 255-80-1
• 化学式: C₈H₈N₂
• 分子量: 132.165
• InChiKey: VFMCUTPRJLZEEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  15.6
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4H-pyrido[1,2-a]pyrimidine 、 9-[(4-乙酰基-3-羟基-2-丙基苯氧基)甲基]-3-(2H-四唑-5-基)吡啶并[2,1-b]嘧啶-4-酮 、 、 、 生成 9-[(4 acetyl-3-hydroxy-2-allylphenoxy)methyl]-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
  参考文献：
  名称：

  Aqueous preparation of pyrido(1,2-a)pyrimidine compound

  摘要：

  一种水性制剂，包括以下化合物的0.1至0.3%（W/V）的吡啶并[1,2-a]嘧啶化合物： ##STR1## 其中R代表n-丙基或烯丙基基团，A代表四唑基或羧基，n代表0至2的整数，0.5至2.0％（W/V）的聚氧乙烯山梨酸酯脂肪酸酯，0.5至2.0％（W/V）的聚乙二醇和1.0至3.5％（W/V）的磷酸氢二钠。

  公开号：

  US05063061A1

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• ALKYLSULFONE DERIVATIVES
  申请人：Iimori Hitoshi

  公开号：US20100168136A1

  公开（公告）日：2010-07-01

  A compound having activity to inhibit production and/or secretion of β-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of β-amyloid protein, the compound represented by the general formula (I): [wherein, R 1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups; R 2 represents a 6-membered nitrogen-containing monocyclic aromatic heterocyclic group having 1 to 3 substituent groups, or a 9- or 10-membered nitrogen-containing bicyclic heterocyclic group having 1 to 4 substituent groups; Z 1 , Z 2 and Z 3 each independently represent a hydrogen atom, a halogen atom or a cyano group; and n represents 0, 1 or 2], salts thereof, or solvates thereof.

  一种具有抑制β-淀粉样蛋白产生和/或分泌活性的化合物，用于预防和/或治疗与β-淀粉样蛋白异常产生和/或分泌相关的各种疾病，该化合物由通式（I）表示：[其中，R1代表可能具有1至6个卤素原子作为取代基的C1-C6烷基，可能具有1至6个卤素原子作为取代基的C2-C6烯基，或可能具有1至6个卤素原子作为取代基的C3-C7环烷基；R2代表具有1至3个取代基的6元氮含量单环芳香杂环基，或具有1至4个取代基的9-或10元氮含量双环杂环基；Z1、Z2和Z3分别独立地代表氢原子、卤素原子或氰基；n代表0、1或2]，其盐或溶剂合物。
• SACCHARIN DERIVATIVES AS ORALLY ACTIVE ELASTASE INHIBITORS
  申请人：——

  公开号：US20030114449A1

  公开（公告）日：2003-06-19

  Orally active compounds of general formula (I) wherein R 1 is methyl, ethyl or 2-morpholino-ethyl group, R 2 is piperidino, morpholino or 4-methyl-piperazinyl group, n is 2 or 3 and their salts, solvates and hydrates.

  通式（I）中的口服活性化合物，其中R1为甲基、乙基或2-吗啉基乙基基团，R2为哌啶基、吗啉基或4-甲基哌嗪基团，n为2或3，以及它们的盐、溶剂合物和水合物。
• VLA-4 INHIBITOR
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1757602A1

  公开（公告）日：2007-02-28

  An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y1 represents a divalent aryl group etc. , V1 represents an aryl group etc., and R11 to R14 represent H, OH or a halogen atom etc.]

  本发明的一个目的是提供一种化合物，该化合物选择性地抑制配体与α4β1整合素（VLA-4）的结合，以及包含该化合物的药物的制备过程。化合物的结构如公式（I）所示，或其盐，制备该化合物或其盐的过程，包含该化合物或其盐的药物，以及作为细胞粘附引起的疾病（例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻阻塞、糖尿病、关节炎、银屑病、多发性硬化症、炎症性肠病和移植排斥反应等）的预防和/或治疗剂，包含该化合物或其盐作为主要成分。【其中Y1代表双价芳基等，V1代表芳基等，R11至R14代表H、OH或卤素原子等】